IDH1 and neoplasm: Of specific note, ≥25% T2-FLAIR mismatch was identified in seven of the eight tumours (87.5%) with a non-canonical IDH mutation, in additional to 30 of the 50 tumours (60%) with an R132H-IDH1 mutation, with no significant difference in the frequency (p=0.299).